|
Diabetes Mellitus, Insulin-Dependent
|
0.090 |
Biomarker
|
disease |
BEFREE |
The aim was to evaluate the effectiveness of sensor-augmented pump therapy with predictive low-glucose suspend function (SAP-PLGS) in real-world use in children and adults with type 1 diabetes (T1D).
|
30256132 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.090 |
Biomarker
|
disease |
BEFREE |
AID = automated insulin delivery; CGM = continuous glucose monitoring; FDA = Food and Drug Administration; HbA1c = glycated hemoglobin; HCL = hybrid closed-loop; ICR = insulin to carbohydrate ratio; SAP = sensor augmented pump; T1DM = type 1 diabetes.
|
30048171 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.090 |
Biomarker
|
disease |
BEFREE |
AACE/ACE Task Force on Integration of Insulin Pumps and Continuous Glucose Monitoring in the Management of Patients With Diabetes Mellitus Chair George Grunberger, MD, FACP, FACE Task Force Members Yehuda Handelsman, MD, FACP, FNLA, MACE Zachary T. Bloomgarden, MD, MACE Vivian A. Fonseca, MD, FACE Alan J. Garber, MD, PhD, FACE Richard A. Haas, MD, FACE Victor L. Roberts, MD, MBA, FACP, FACE Guillermo E. Umpierrez, MD, CDE, FACP, FACE Abbreviations: AACE = American Association of Clinical Endocrinologists ACE = American College of Endocrinology A1C = glycated hemoglobin BGM = blood glucose monitoring CGM = continuous glucose monitoring CSII = continuous subcutaneous insulin infusion DM = diabetes mellitus FDA = Food & Drug Administration MDI = multiple daily injections T1DM = type 1 diabetes mellitus T2DM = type 2 diabetes mellitus SAP = sensor-augmented pump SMBG = self-monitoring of blood glucose STAR 3 = Sensor-Augmented Pump Therapy for A1C Reduction phase 3 trial.
|
29547046 |
2018 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.090 |
Biomarker
|
disease |
BEFREE |
We did a systematic review and meta-analysis of randomised controlled trials comparing artificial pancreas systems (insulin only or insulin plus glucagon) with conventional pump therapy (continuous subcutaneous insulin infusion [CSII] with blinded continuous glucose monitoring [CGM] or unblinded sensor-augmented pump [SAP] therapy) in adults and children with type 1 diabetes.
|
28533136 |
2017 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.090 |
Biomarker
|
disease |
BEFREE |
This isoform competes with the wild-type LYP for binding to CSK and results in hyporesponsiveness of CD4(+) T cells to antigen stimulation in T1D subjects.
|
26631741 |
2016 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The protein tyrosine phosphatase LYP, a key regulator of TCR signaling, presents a single nucleotide polymorphism, C1858T, associated with several autoimmune diseases such as type I diabetes, rheumatoid arthritis, and lupus.
|
23359562 |
2013 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the LYP 620Trp variant is associated with reduced activation, proliferation and IL-2 production in CD4(+)T cells among T1D patients.
|
18299186 |
2008 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Association of the PTPN22/LYP gene with type 1 diabetes.
|
17054449 |
2006 |
|
Diabetes Mellitus, Insulin-Dependent
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Variation of two molecules that negatively regulate T cells, CTLA-4 and the tyrosine phosphatase LYP/PEP, are associated with susceptibility to human and NOD T1D.
|
16257508 |
2005 |